Senior Director of Biotechnology at Catalent To Lead Immunogenicity Course
Released
on: December 03, 2009, 01:28 pm
Author:
Jennings and Co.
Industry: Pharmaceuticals
Ana T. Menendez, Ph.D., Senior Director of Biotechnology at
Catalent Pharma Solutions, will lead a two-day international course on
immunogenicity. The course will take place at the Regus Victoria in
London on Wednesday, December 2 through Thursday, December 3, 2009.
The interactive course, titled “Introduction to Immunogenicity,” will enable
attendees to better understand ways to detect, reduce and characterize unwanted
immunogenicity. Additionally, Menendez will aid in interpreting the latest
regulatory guidelines, and will assist attendees in formulating a winning strategy
to implement in their business immediately.
The sessions will include a formal presentation by Menendez followed by facilitated
breakout groups where delegates will be given the opportunity to apply the
principles taught in the sections. Case studies, cut-point exercises and protocol
workshops will increase the participants’ hands-on experience in developing and
validating sensitive and rugged methods to detect and characterize unwanted
immunogenicity.
As part of Catalent’s Development and Clinical Services Segment, Dr. Menendez is
responsible for the release tests required to verify the functionality and purity of
biotechnology products and the complex processes involved in their manufacture.
Menendez implemented biotesting at Catalent and currently leads the following
laboratories at the North Carolina Research Triangle Park facility: Cellular
Technologies, Molecular Technologies, Virology and Analytical Biosafety. The
expertise of the department ranges from proteins (i.e., monoclonal antibodies,
enzymes, growth factors) to therapeutic viruses, bacterial vaccines and aptamers.
Menenedez is an international instructor on bioassay development and validation and
a frequent speaker at biopharmaceutical conferences.
For more information on Catalent’s broad range of drug and biologic development
services, go to www.catalent.com/development.
About Catalent
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading
provider of advanced dose form and packaging technologies, and development,
manufacturing and packaging services for pharmaceutical, biotechnology and consumer
healthcare companies in nearly 100 countries. Catalent applies its local market
expertise and technical creativity to advance treatments, change markets and enhance
patient outcomes. Catalent employs approximately 9,500 at 30 facilities worldwide
and in fiscal 2009 generated more than $1.6 billion of annual revenue. For more
information, visit www.catalent.com.
Contact Details: Dan Dunlop, Jennings
Peggy Albertson, Jennings
919- 929-0225
ddunlop@jenningsco.com
palbertson@jenningsco.com
2010
